Evidence map›Paper›PMID 38845188›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Generation and Characterization of Novel Pan-Cancer Anti-uPAR Fluorescent Nanobodies as Tools for Image-Guided Surgery.

Łukasz Mateusiak, Sam Floru, Timo W M De Groof, Janne Wouters, Noemi B Declerck, Pieterjan Debie, Simone Janssen, Katty Zeven, Janik Puttemans, Cécile Vincke and 3 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Łukasz MateusiakLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.ORCID 0000-0002-2837-8342
Sam FloruLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Timo W M De GroofLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Janne WoutersLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Noemi B DeclerckLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Pieterjan DebieLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Simone JanssenLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Katty ZevenLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Janik PuttemansLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Cécile VinckeLaboratory for Cellular and Molecular Immunology, Vrije Universiteit Brussel (VUB), Pleinlaan 2, Brussels, 1050, Belgium.
Karine BreckpotLaboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, Brussels, 1090, Belgium.
Nick DevoogdtLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.
Sophie HernotLaboratory for Molecular Imaging and Therapy, Vrije Universiteit Brussel (VUB), MITH, Laarbeeklaan 103, Brussels, 1090, Belgium.

Funding

Fonds Wetenschappelijk Onderzoek FWOSBO42Industrial Research Fund IOF3005Stichting Tegen Kanker ANI183Strategic Research Program SRP50
6 · The paper itself

Abstract

Fluorescence molecular imaging plays a vital role in image-guided surgery. In this context, the urokinase plasminogen activator receptor (uPAR) is an interesting biomarker enabling the detection and delineation of various tumor types due to its elevated expression on both tumor cells and the tumor microenvironment. In this study, anti-uPAR Nanobodies (Nbs) are generated through llama immunization with human and murine uPAR protein. Extensive in vitro characterization and in vivo testing with radiolabeled variants are conducted to assess their pharmacokinetics and select lead compounds. Subsequently, the selected Nbs are converted into fluorescent agents, and their application for fluorescence-guided surgery is evaluated in various subcutaneous and orthotopic tumor models. The study yields a panel of high-affinity anti-uPAR Nbs, showing specific binding across multiple types of cancer cells in vitro and in vivo. Lead fluorescently-labeled compounds exhibit high tumor uptake with high contrast at 1 h after intravenous injection across all assessed uPAR-expressing tumor models, outperforming a non-targeting control Nb. Additionally, rapid and accurate tumor localization and demarcation are demonstrated in an orthotopic human glioma model. Utilizing these Nbs can potentially enhance the precision of surgical tumor resection and, consequently, improve survival rates in the clinic.

Indexed as

Receptors, Urokinase Plasminogen ActivatorSingle-Domain AntibodiesSurgery, Computer-AssistedAnimalsCamelids, New WorldCell Line, TumorDisease Models, AnimalFluorescent DyesHumansMiceNeoplasmsOptical ImagingFluorescent DyesReceptors, Urokinase Plasminogen ActivatorSingle-Domain Antibodiesfluorescence‐guided surgeryfluorescence molecular imagingsingle‐domain antibodiesurokinase plasminogen activator receptor

Identifiers

PMID38845188
PMCPMC11321701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.